Design and synthesis of new α-naphthoflavones as cytochrome P450 (CYP) 1B1 inhibitors to overcome docetaxel-resistance associated with CYP1B1 overexpression

Journal of Medicinal Chemistry

Volumn 58, Issue 8, 2015, Pages 3534-3547

  Cui, Jiahua ^a   Meng, Qingqing ^a   Zhang, Xu ^a   Cui, Qing ^a   Zhou, Wen ^a   Li, Shaoshun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 (3' FLUORO 6,7,10 TRIMETHOXY ALPHA NAPHTHOFLAVONOL)ETHOXY] 2 OXOETHANAMINIUM CHLORIDE; 2' CHLORO 6,7,10 TRIMETHOXY ALPHA NAPHTHOFLAVONE; 2' CHLORO 6,7,10 TRIMETHOXY ALPHA NAPHTHOFLAVONOL; 2' FLUORO 6,7,10 TRIMETHOXY ALPHA NAPHTHOFLAVONE; 2' FLUORO 6,7,10 TRIMETHOXY ALPHA NAPHTHOFLAVONOL; 2' HYDROXY 6,7,10 TRIMETHOXY ALPHA NAPHTHOFLAVONE; 2',6,7,10 TETRAMETHOXY ALPHA NAPHTHOFLAVONE; 3' CHLORO 6,7,10 TRIMETHOXY ALPHA NAPHTHOFLAVONE; 3' CHLORO 6,7,10 TRIMETHOXY ALPHA NAPHTHOFLAVONOL; 3' FLUORO 6,7,10 TRIMETHOXY ALPHA NAPHTHOFLAVONE; 3' FLUORO 6,7,10 TRIMETHOXY ALPHA NAPHTHOFLAVONOL; 3',4' BIS(BENZYLOXY) 6,7,10 TRIMETHOXY ALPHA NAPHTHOFLAVONE; 3',4',5',6,7,10 HEXAMETHOXY ALPHA NAPHTHOFLAVONE; 3',4',6,7,10 PENTAMETHOXY ALPHA NAPHTHOFLAVONE; 4 BENZYLOXY 6,7,10 TRIMETHOXY ALPHA NAPHTHOFLAVONE; 4' CHLORO 6,7,10 TRIMETHOXY ALPHA NAPHTHOFLAVONE; 4' CHLORO 6,7,10 TRIMETHOXY ALPHA NAPHTHOFLAVONOL; 4' FLUORO 6,7,10 TRIMETHOXY ALPHA NAPHTHOFLAVONE; 4' FLUORO 6,7,10 TRIMETHOXY ALPHA NAPHTHOFLAVONOL; 4' HYDROXY 6,7,10 TRIMETHOXY ALPHA NAPHTHOFLAVONE; 4',6,7,10 TETRAMETHOXY ALPHA NAPHTHOFLAVONE; 6,7,10 TRIMETHOXY ALPHA NAPHTHOFLAVONE; ALPHA NAPHTHOFLAVONE; ANTINEOPLASTIC AGENT; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 INHIBITOR; DOCETAXEL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ALPHA-NAPHTHOFLAVONE; BENZOFLAVONE DERIVATIVE; TAXOID;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CRYSTAL STRUCTURE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG RESISTANCE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROGEN BOND; IC50; IN VITRO STUDY; MOLECULAR DOCKING; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; METABOLISM; NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZOFLAVONES; CELL LINE, TUMOR; CYTOCHROME P-450 CYP1B1; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR DOCKING SIMULATION; NEOPLASMS; TAXOIDS;

EID: 84928492568     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00265     Document Type: Article

References (44)

1. Shimada, T.; Hayes, C. L.; Yamazaki, H.; Amin, S.; Hecht, S. S.; Guengerich, F. P.; Sutter, T. R. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1 Cancer Res. 1996, 56, 2979-2984
2. Peter Guengerich, F.; Chun, Y. J.; Kim, D.; Gillam, E. M.; Shimada, T. Cytochrome P450 1B1: A target for inhibition in anticarcinogenesis strategies Mutat. Res. 2003, 523-524, 173-182
3. Yamazaki, H.; Hatanaka, N.; Kizu, R.; Hayakawa, K.; Shimada, N.; Guengerich, F. P.; Nakajima, M.; Yokoi, T. Bioactivation of diesel exhaust particle extracts and their major nitrated polycyclic aromatic hydrocarbon components, 1-nitropyrene and dinitropyrenes, by human cytochromes P450 1A1, 1A2, and 1B1 Mutat. Res., Genet. Toxicol. Environ. Mutagen. 2000, 472, 129-138
4. Hayes, C. L.; Spink, D. C.; Spink, B. C.; Cao, J. Q.; Walker, N. J.; Sutter, T. R. 17-beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1 Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 9776-9781
5. Van Aswegen, C. H.; Purdy, R. H.; Wittliff, J. L. Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to estrogen receptors from human breast cancers J. Steroid Biochem. 1989, 32, 485-492
6. Schutze, N.; Vollmer, G.; Tiemann, I.; Geiger, M.; Knuppen, R. Catecholestrogens are MCF-7 cell estrogen receptor agonists J. Steroid Biochem. Mol. Biol. 1993, 46, 781-789
7. Lee, A. J.; Cai, M. X.; Thomas, P. E.; Conney, A. H.; Zhu, B. T. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms Endocrinology 2003, 144, 3382-3398
8. Zhao, Z.; Kosinska, W.; Khmelnitsky, M.; Cavalieri, E. L.; Rogan, E. G.; Chakravarti, D.; Sacks, P. G.; Guttenplan, J. B. Mutagenic activity of 4-hydroxyestradiol, but not 2-hydroxyestradiol, in BB rat2 embryonic cells, and the mutational spectrum of 4-hydroxyestradiol Chem. Res. Toxicol. 2006, 19, 475-479
9. McKay, J. A.; Melvin, W. T.; Ah-See, A. K.; Ewen, S. W.; Greenlee, W. F.; Marcus, C. B.; Burke, M. D.; Murray, G. I. Expression of cytochrome P450 CYP1B1 in breast cancer FEBS Lett. 1995, 374, 270-272
10. Murray, G. I.; Taylor, M. C.; McFadyen, M. C.; McKay, J. A.; Greenlee, W. F.; Burke, M. D.; Melvin, W. T. Tumor-specific expression of cytochrome P450 CYP1B1 Cancer Res. 1997, 57, 3026-3031
11. McFadyen, M. C.; Cruickshank, M. E.; Miller, I. D.; McLeod, H. L.; Melvin, W. T.; Haites, N. E.; Parkin, D.; Murray, G. I. Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer Br. J. Cancer 2001, 85, 242-246
12. McFadyen, M. C.; Melvin, W. T.; Murray, G. I. Cytochrome P450 CYP1B1 activity in renal cell carcinoma Br. J. Cancer 2004, 91, 966-971
13. McFadyen, M. C.; McLeod, H. L.; Jackson, F. C.; Melvin, W. T.; Doehmer, J.; Murray, G. I. Cytochrome P450 CYP1B1 protein expression: A novel mechanism of anticancer drug resistance Biochem. Pharmacol. 2001, 62, 207-212
14. Rochat, B.; Morsman, J. M.; Murray, G. I.; Figg, W. D.; McLeod, H. L. Human CYP1B1 and anticancer agent metabolism: Mechanism for tumor-specific drug inactivation? J. Pharmacol. Exp. Ther. 2001, 296, 537-541
15. McFadyen, M. C.; Murray, G. I. Cytochrome P450 1B1: A novel anticancer therapeutic target Future Oncol. 2005, 1, 259-263
16. Chun, Y. J.; Kim, S. Discovery of cytochrome P450 1B1 inhibitors as new promising anti-cancer agents Med. Res. Rev. 2003, 23, 657-668
17. Cui, J.; Li, S. Inhibitors and prodrugs targeting CYP1: A novel approach in cancer prevention and therapy Curr. Med. Chem. 2014, 21, 519-552
18. Androutsopoulos, V. P.; Papakyriakou, A.; Vourloumis, D.; Tsatsakis, A. M.; Spandidos, D. A. Dietary flavonoids in cancer therapy and prevention: Substrates and inhibitors of cytochrome P450 CYP1 enzymes Pharmacol. Ther. 2010, 126, 9-20
19. Chang, T. K.; Lee, W. B.; Ko, H. H. Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1 Can. J. Physiol. Pharmacol. 2000, 78, 874-81
20. Mikstacka, R.; Dutkiewicz, Z.; Sobiak, S.; Baer-Dubowska, W. The Inhibitory Effect of Natural Stilbenes and Their Analogues on Catalytic Activity of Cytochromes P450 Family 1 in Comparison with Other Phenols-Structure and Activity Relationship. In Phytochemicals-A Global Perspective of Their Role in Nutrition and Health; Rao, V., Ed.; InTech: Rijeka, Croatia, 2012; pp 519-538. Available from: http://www.intechopen.com/books/phytochemicals-a-global-perspective-of-their-role-in-nutrition-and-health/the-inhibitory-effect-of-natural-stilbenes-and-their-analogs-on-catalytic-activity-of-cytochromes-p4.
21. Cui, J.; Li, S. Structure, chemistry and pharmacology of naphthoflavones Mini-Rev. Med. Chem. 2013, 13, 1357-1368
22. Shimada, T.; Yamazaki, H.; Foroozesh, M.; Hopkins, N. E.; Alworth, W. L.; Guengerich, F. P. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1 Chem. Res. Toxicol. 1998, 11, 1048-1056
23. Cui, J.; Zhou, W.; Li, S. A convenient and efficient synthesis of 2-acetyl-5,8-dimethoxy-1,4-naphthoquinone J. Chem. Res. 2012, 36, 264-265
24. Geissman, T. A.; Fukushima, D. K. Flavonones and related compounds. V. The oxidation of 2′-hydroxychalcones with alkaline hydrogen peroxide J. Am. Chem. Soc. 1948, 70, 1686-1689
25. Li, Z.; Ngojeh, G.; DeWitt, P.; Zheng, Z.; Chen, M.; Lainhart, B.; Li, V.; Felpo, P. Synthesis of a library of glycosylated flavonols Tetrahedron Lett. 1996, 49, 7243-7245
26. Qin, C. X.; Chen, X.; Hughes, R. A.; Williams, S. J.; Woodman, O. L. Understanding the cardioprotective effects of flavonols: Discovery of relaxant flavonols without antioxidant activity J. Med. Chem. 2008, 51, 1874-1884
27. Kurzwernhart, A.; Kandioller, W.; Bartel, C.; Bachler, S.; Trondl, R.; Muhlgassner, G.; Jakupec, M. A.; Arion, V. B.; Marko, D.; Keppler, B. K.; Hartinger, C. G. Targeting the DNA-topoisomerase complex in a double-strike approach with a topoisomerase inhibiting moiety and covalent DNA binder Chem. Commun. 2012, 48, 4839-4841
28. Fougerousse, A.; Gonzalez, E.; Brouillard, R. A convenient method for synthesizing 2-aryl-3-hydroxy-4-oxo-4 H -1- benzopyrans or flavonols J. Org. Chem. 2000, 65, 583-586
29. Dean, F. M.; Podimuang, V. 737. The course of the Algar-Flynn-Oyamada (A.F.O.) reaction J. Chem. Soc. 1965, 3978-3987
30. Yamaori, S.; Kushihara, M.; Yamamoto, I.; Watanabe, K. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes Biochem. Pharmacol. 2010, 79, 1691-1698
31. Mahal, H. S.; Venkataraman, K. Synthetical experiments in the chromone group. Part XIV. The action of sodamide on 1-acyloxy-2-acetonaphthones J. Chem. Soc. 1934, 1767-1769
32. Wang, A.; Savas, U.; Stout, C. D.; Johnson, E. F. Structural characterization of the complex between α-naphthoflavone and human cytochrome P450 1B1 J. Biol. Chem. 2011, 286, 5736-5743
33. Sansen, S.; Yano, J. K.; Reynald, R. L.; Schoch, G. A.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2 J. Biol. Chem. 2007, 282, 14348-14355
34. Walsh, A. A.; Szklarz, G. D.; Scott, E. E. Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism J. Biol. Chem. 2013, 288, 12932-12943
35. Meunier, B.; de Visser, S. P.; Shaik, S. Mechanism of oxidation reactions catalyzed by cytochrome p450 enzymes Chem. Rev. 2004, 104, 3947-3980
36. Petrek, M.; Kosinova, P.; Koca, J.; Otyepka, M. MOLE: A Voronoi diagram-based explorer of molecular channels, pores, and tunnels Structure 2007, 15, 1357-1363
37. Martinez, V. G.; O'Connor, R.; Liang, Y.; Clynes, M. CYP1B1 expression is induced by docetaxel: Effect on cell viability and drug resistance Br. J. Cancer 2008, 98, 564-570
38. Sutter, T. R.; Tang, Y. M.; Hayes, C. L.; Wo, Y. Y.; Jabs, E. W.; Li, X.; Yin, H.; Cody, C. W.; Greenlee, W. F. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2 J. Biol. Chem. 1994, 269, 13092-13099
39. Spink, D. C.; Hayes, C. L.; Young, N. R.; Christou, M.; Sutter, T. R.; Jefcoate, C. R.; Gierthy, J. F. The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on estrogen metabolism in MCF-7 breast cancer cells: Evidence for induction of a novel 17-beta-estradiol 4-hydroxylase J. Steroid Biochem. Mol. Biol. 1994, 51, 251-258
40. Spink, D. C.; Spink, B. C.; Cao, J. Q.; DePasquale, J. A.; Pentecost, B. T.; Fasco, M. J.; Li, Y.; Sutter, T. R. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells Carcinogenesis 1998, 19, 291-298
41. Armarego, W. L. F.; Chai, C. L. L. Purification of Laboratory Chemicals, 6 th ed.; Butterworth-Heinemann: Burlington, VT, 2009.
42. Bandiera, S.; Weidlich, S.; Harth, V.; Broede, P.; Ko, Y.; Friedberg, T. Proteasomal degradation of human CYP1B1: Effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression Mol. Pharmacol. 2005, 67, 435-443
43. Sambrook, J. F.; Russell, D. W. Molecular Cloning: A Laboratory Manual, 3 rd ed.; Cold Spring Harbor Laboratory Press: Woodbury, NY, 2001.
44. Zhou, W.; Peng, Y.; Li, S. S. Semi-synthesis and anti-tumor activity of 5,8-O-dimethyl acylshikonin derivatives Eur. J. Med. Chem. 2010, 45, 6005-6011